Subcutaneous Amivantamab Plus Lazertinib Yields High Response In Egfr-mutant Lung Cancer

A caller study from nan PALOMA-2 study presented coming shows that subcutaneous management of amivantamab each 4 weeks (Q4W), successful operation pinch regular oral lazertinib, yields a precocious nonsubjective consequence complaint successful patients pinch antecedently untreated EGFR-mutated precocious non-small compartment lung crab (NSCLC).

The results were presented astatine nan International Association for nan Study of Lung Cancer astatine nan 2025 World Conference connected Lung Cancer (WCLC).

In nan afloat enrolled Cohort 5 of nan PALOMA-2 trial, nan Q4W dosing regimen was shown to support akin efficacy compared to humanities intravenous (IV) and Q2W subcutaneous data, while offering less administration-related reactions and improved convenience for patients.

"Subcutaneous amivantamab dosed erstwhile a period offers a little burdensome curen action without compromising efficacy," said Dr. Susan Scott, from The Sidney Kimmel Comprehensive Cancer Center astatine Johns Hopkins University. "These information support nan imaginable for Q4W management to heighten value of life for patients pinch EGFR-mutant NSCLC."

Dr. Scott and her colleagues enrolled 77 treatment-naïve participants pinch EGFR Ex19del aliases L858R mutations. Median property was 63 years; 68% of participants were female, and 62% were Asian. Brain metastases were coming successful 43% of participants astatine screening.

She reported nan pursuing results from nan study:

• Objective consequence complaint (ORR): 82% by investigator, 87% by independent cardinal reappraisal (ICR).
• Confirmed ORR: 79% by investigator, 83% by ICR.
• Median clip to response: 8.1 weeks.
• Median long of response, PFS, and wide endurance were not yet reached astatine 6.5 months follow-up.

Most adverse events were related to EGFR/MET inhibition, including paronychia, rash, and hypoalbuminemia. Administration-related reactions (ARRs) occurred successful only 12% of participants, pinch conscionable 1 Grade ≥3 ARR reported. Venous thromboembolic events (VTEs) were reported successful 13% of participants, though nary were Grade ≥3, and bleeding events were uncommon (1%).

No caller information signals were identified. Only 8% of patients discontinued amivantamab owed to treatment-related adverse events. The mean plasma attraction levels were accordant pinch humanities IV and Q2W subcutaneous dosing data, supporting pharmacokinetic equivalency.

"These findings support nan continued improvement of subcutaneous Q4W amivantamab arsenic a convenient, effective frontline therapy for EGFR-mutated NSCLC," Dr. Scott reported.